Lars Hellerung Christiansen has more than 30 years of experience as a serial entrepreneur in biotech and pharma. The astute businessman with a striking track record visited Verve Venture’s flagship investor event together with Karsten Lindhardt, the CEO of Biograil. In this interview, Lars shares some of his experience in how to identify promising startups and help them succeed.

Lars Hellerung Christiansen
Investor, Advisor, Serial Entrepreneur

Lars Hellerung Christiansen is an advisor and investor of Biograil, a Danish drug delivery startup. He has co-founded 3 companies that did an IPO on the NASDAQ stock exchange: Acadia Pharmaceutical, Zealand Pharma, and Epizyme. Another company he co-founded, Prosidion, merged with OSI Pharmaceutical which was acquired by Astellas Pharma for USD 4 billion. He has co-founded several other biotech startups that are still privately held eg. Symphogen. The latest company he co-founded is Afix Therapeutics which develops a novel delivery system for diseases in the mouth and is currently in phase IIb trials. In 2017, Lars was nominated for the E&Y life sciences entrepreneur of the year award.

The deep-tech VC of choice for entrepreneurial investors

Since 2010, we have invested in 180 European deep tech companies based on topical experience. With a highly skilled team of investment professionals, we back outstanding entrepreneurs driving growth in key industries. Verve is the pioneer of deep tech in Europe.